Clinical Laboratory Services Bi-Weekly Industry Events & M&A Update — September 14–28, 2026

Read the report

SlidesScroll

1 of 7

←→Full screen

BI-WEEKLY INDUSTRY EVENTS & M&A UPDATE

HEALTH CARE › HEALTH CARE EQUIPMENT AND SERVICES › CLINICAL LABORATORY SERVICES

Regulatory Wins Lift the Leaders While the Deal Record Stays Quiet

This update covers movers, company announcements and transaction activity across Clinical Laboratory Services for September 14–28, 2026.

September 14–28, 2026

Prepared by NeuraCap AI · Confidential

Market data through 2026-09-28 · events and transactions from the two-week period 2026-09-14 → 2026-09-28

Clinical Laboratory Services Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice

Sources & methodology

1

← Previous

1 / 7 · HEALTH CARE › HEALTH CARE EQUIPMENT AND SERVICES › CLINICAL LABORATORY SERVICES

Next →

What each page shows

The analyst’s walkthrough of the deck, page by page.

1. 01
   BI-WEEKLY INDUSTRY EVENTS & M&A UPDATE

   HEALTH CARE › HEALTH CARE EQUIPMENT AND SERVICES › CLINICAL LABORATORY SERVICES

   This is the cover slide introducing the Clinical Laboratory Services bi-weekly update for September 14–28, 2026.

   We open this bi-weekly update on Clinical Laboratory Services, covering the two weeks of September 14–28, 2026. In the pages that follow, we walk through what moved, what companies announced, what transacted, and what it means for the sector.

   Everything on this page

   BI-WEEKLY INDUSTRY EVENTS & M&A UPDATE HEALTH CARE › HEALTH CARE EQUIPMENT AND SERVICES › CLINICAL LABORATORY SERVICES Regulatory Wins Lift the Leaders While the Deal Record Stays Quiet This update covers movers, company announcements and transaction activity across Clinical Laboratory Services for September 14–28, 2026. September 14–28, 2026 Prepared by NeuraCap AI · Confidential Market data through 2026-09-28 · events and transactions from the two-week period 2026-09-14 → 2026-09-28 Clinical Laboratory Services Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice Sources & methodology 1

2. 02
   THE BI-WEEKLY BOTTOM LINE

   Coverage, Coding and Clearance Milestones Set the Direction, Not Transactions

   This slide states the bi-weekly bottom line: coverage, coding and clearance milestones — not transactions — set the sector's direction.

   Across the 20 names we cover, 14 rose over the two-week period and the median move was +7.9%, well ahead of the S&P 500's +0.8%. The gains clustered in names that put a regulatory or reimbursement development on the record inside the window, which tells us where the market is placing its conviction. So what: for this stretch, evidence and coverage decisions carried more weight than deal activity.

   Everything on this page

   THE BI-WEEKLY BOTTOM LINE Coverage, Coding and Clearance Milestones Set the Direction, Not Transactions The two-week period in one page · 20 covered names, close-to-close · September 14–28, 2026 Source: NeuraCap analytics platform (universe, prices, filings, transaction records); publisher-sourced news where linked; market data through 2026-09-28. Driver attributions use calibrated language and are NeuraCap reads of the recorded evidence. Clinical Laboratory Services Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice Sources & methodology 2 1 14 of 20 Covered Names Rose; The Median Move Was +7.9% The covered set ran ahead of the S&P 500's +0.8% over the two-week period. The gains clustered in names that put a regulatory or reimbursement development on the record inside the window. 2 Regulatory Decisions Did the Heavy Lifting GRAIL, Inc. (GRAL), a Premium-tier name in NeuraCap's standing sector view, rose +75.6% over the period with a +33.7% single-day move on Sep 21. Tempus AI, Inc. (TEM) rose +36.8% across a run of licensing and clearance announcements. 3 The 2027 Fee Schedule Moved into the Conversation A Sep 23 Benzinga item reported that CMS plans to align 2027 clinical laboratory fee schedule rates with private payer rates, an estimated $1b of Medicare savings, and read the change differently for BillionToOne, Inc. (BLLN) and CareDx, Inc (CDNA). CareDx rose +23.4% over the period. 4 The Transaction Record Added No New Entries Nothing new landed in the precedent set during the window, so the listed comparable group remains the reference. NeuraCap's standing lens for the sector is EV / Revenue on CY2027E, with a 4.5x sector median. +85.6% Best mover — YDES worst: IMDX -20.9% · 14 up / 6 down of 20 covered +7.9% Sector median two-week return vs S&P 500 +0.8%

3. 03
   PUBLIC MARKET MOVERS

   The Biggest Moves Followed Decisions on Coverage, Coding and Clearance

   This slide ranks the period's biggest share-price moves and ties each to the coverage, coding or clearance decision behind it.

   GRAIL (GRAL) led the covered set with a +75.6% move over the period, including a +33.7% single-day jump on Sep 21 tied to an FDA advisory vote. Tempus AI (TEM) rose +36.8% on a run of licensing and clearance announcements, and CareDx (CDNA) added +23.4% against the CMS fee-schedule conversation. We apply a ±13.5% sector-relative materiality bar, and every attribution here links only to a recorded filing or headline inside the window. So what: the names that moved the most were the names that put new regulatory or reimbursement evidence on the record.

   Everything on this page

   PUBLIC MARKET MOVERS The Biggest Moves Followed Decisions on Coverage, Coding and Clearance Bi-Weekly moves, close-to-close · September 14–28, 2026 · sector median +7.9% · S&P 500 +0.8% · materiality bar ±13.5% (sector-relative) Source: NeuraCap analytics platform (universe, prices, filings, transaction records); publisher-sourced news where linked; market data through 2026-09-28. Attribution links each move only to filings and headlines recorded in the window; where no driver is recorded, the page says so. Calibrated language throughout — NeuraCap reads, not asserted causation. Clinical Laboratory Services Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice Sources & methodology 3 Bi-Weekly return per company · teal above zero, amber below · sector median +7.9% YD Bio Limited Ordinary Shares (YDES) +85.6% No notable in-window news was identified that clearly explains the move. The +85.6% two-week gain ran well ahead of the +7.9% median across covered names. Smaller diagnostics names can travel a long way from the covered-set median inside a single two-week window. UNEXPLAINED GRAIL, Inc. (GRAL) +75.6% Shares moved following Reuters' Sep 21 report that FDA staff reviewers flagged no major concerns on the Galleri multi-cancer early detection test, and then the Sep 23 advisory committee vote in favour of approval announced by the company. For screening assets, the regulatory milestone is the commercial unlock, and the market prices it on the day it lands. COMPANY-SPECIFIC Tempus AI, Inc. (TEM) +36.8% The move appears to reflect a run of in-window announcements: an extended data licence and a new licence covering a partner's RNA foundation model on Sep 21, followed by FDA 510(k) clearance for the Tempus ECG-MR AI product on Sep 28. A biopharma data franchise alongside clinical testing is being valued as a second earnings engine, not a side line. COMPANY-SPECIFIC Insight Molecular Diagnostics Inc. (IMDX) -20.9% No notable in-window news was identified that clearly explains the move. The -20.9% two-week move sat well below the +7.9% median across covered names. Direction was not uniform: six of the twenty covered names finished the period lower. UNEXPLAINED

4. 04
   MAJOR NEWS & INDUSTRY CATALYSTS

   Companies Spent the Period Building Coverage, Coding and Menu

   This slide lists the two-week period's highest-impact company announcements, each linked to its underlying filing or article.

   The period's news flow centered on coverage, coding and menu-building steps rather than deal-making. Each item on this page links to its source, and our 'why it matters' read is clearly separated from the recorded fact. So what: this is the evidence file we'd point a client to before relying on any single headline.

   Everything on this page

   MAJOR NEWS & INDUSTRY CATALYSTS Companies Spent the Period Building Coverage, Coding and Menu The two-week period's highest-impact events · titles link to the underlying filing or article · September 14–28, 2026 Source: NeuraCap analytics platform (universe, prices, filings, transaction records); publisher-sourced news where linked; market data through 2026-09-28. "Why it matters" lines are NeuraCap reads; each event links to its source. Sources are admitted in a fixed reliability order (SEC filings, press releases, established outlets); video and social platforms are never used. Clinical Laboratory Services Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice Sources & methodology 4 Sep 22 · NEWS · PRNewsWire Castle Biosciences to open a new laboratory facility in Scottsdale, Arizona Added lab capacity is a bet on accessioned volume growth and on cost per accession falling as that volume absorbs a fixed footprint. Capacity decisions are being taken ahead of volume, which only works where the ordering base is already expanding. Sep 22 · NEWS · PRNewsWire Lucid Diagnostics advances EsoGuard payment basis and wins a new Category III code for EsoCheck A Medicare advisory panel recommendation on the gapfill payment basis plus a new CPT code speak directly to reimbursement durability, the gate between a test performed and a dollar collected. Coding and payment decisions, taken one assay at a time, are where specialty labs build defensible economics. Sep 22 · NEWS · Business Wire Natera wins Japanese regulatory approval for Signatera as a companion diagnostic in bladder cancer A companion diagnostic approval in a second major market widens the indication footprint and strengthens the biopharma side of the franchise. Geographic and indication expansion on an existing assay is a cheaper route to revenue than a new menu build. Sep 21 · NEWS · Business Wire Tempus extends its data licence and adds a new licence for a partner's RNA foundation model Data licensing turns the clinical testing archive into contracted revenue that behaves differently from accessioned volume. Laboratory data assets are being contracted, and that revenue line is now part of how these businesses are framed. Sep 18 · NEWS · Business Wire Natera presents lung cancer MRD data showing strong prognostic value for Signatera Clinical utility evidence at a major conference is the input to guideline inclusion, which is what converts ordering interest into routine ordering behaviour. Evidence programmes remain the long-cycle cost that decides which assays earn payer coverage. Sep 16 · NEWS · GlobeNewsWire Executives disclose roughly $629,000 of open-market share purchases after positive Phase 2a results Open-market buying by management alongside a clinical readout is a visible signal about how insiders view the company's position after the data. In evidence-stage names, insider action is read as a supplement to the data, not a substitute for coverage.

5. 05
   M&A & STRATEGIC ACTIVITY

   Buyers Stayed on the Sidelines While Operators Advanced Their Own Evidence

   This slide reviews M&A and strategic activity for the period against the standing set of 40 recorded precedent transactions.

   No new transactions entered the precedent record during September 14–28, 2026, so the existing 40-deal comparable set remains the reference for pricing conversations. Buyers stayed on the sidelines while operators continued building their own regulatory and reimbursement evidence instead. So what: absent new deal evidence, the listed comparables — and how the market is pricing them today — are what a pricing conversation has to run off.

   Everything on this page

   M&A & STRATEGIC ACTIVITY Buyers Stayed on the Sidelines While Operators Advanced Their Own Evidence September 14–28, 2026 · precedent transactions: 40 recorded deals Source: NeuraCap analytics platform (universe, prices, filings, transaction records); publisher-sourced news where linked; market data through 2026-09-28. Deal multiples are LTM at announcement where disclosed; "why the deal happened" is a NeuraCap read of the recorded evidence. No old transactions are re-presented as news. Clinical Laboratory Services Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice Sources & methodology 5 No Material Transactions Announced No material sector transactions were announced during the period. The observable buyer activity was menu-level: Veracyte, Inc. (VCYT) announced on Sep 14 that it had acquired a urinary tumour DNA testing platform to widen its urology portfolio. A quiet two-week period is information: buyer appetite, financing conditions and seller expectations all read through a period with no new deals. The precedent transactions alongside still frame what buyers have paid. 40 Recorded precedent transactions the reference set buyers and sellers price against

6. 06
   WHAT IT MEANS

   What the Period Means for Operators, Buyers and Advisors

   This slide translates the period's evidence into observations for operators, buyers and advisors.

   For operators, the period rewarded reimbursement conversion — coverage, coding and clearance milestones moved share prices, not deal announcements. For acquirers, the listed comparable set is still the reference point since no new precedent transactions entered the record. For advisors, the evidence file to lead with is concrete: the GRAIL (GRAL) advisory vote and Tempus AI (TEM) clearance and licensing news. So what: these are observations on the recorded evidence, not recommendations to act.

   Everything on this page

   WHAT IT MEANS What the Period Means for Operators, Buyers and Advisors The two-week period translated for the people who act on it · NeuraCap view · observations, not recommendations Source: NeuraCap analytics platform (universe, prices, filings, transaction records); publisher-sourced news where linked; market data through 2026-09-28. This page is analytical interpretation drawn from the two-week period's recorded evidence. It is not investment advice. Clinical Laboratory Services Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice Sources & methodology 6 Sector study 2026-09-28 EV / Revenue (CY2027E) median 4.5x 22 companies in the study 3 valuation tiers Standing thesis: Clinical Laboratory Services spans scaled lab networks, specialty diagnostics and adjacent models FOR OWNERS & OPERATORS Reimbursement Conversion Is What the Period Rewarded Companies in the space traded higher on coverage, coding and clearance milestones. The KPIs behind that are the familiar ones: accessioned volume by clinical, biopharma and screening channel, average reimbursement per test FOR ACQUIRERS The Listed Comparable Set Is Still the Reference Point No new precedent transactions entered the record during the two-week period, so pricing conversations continue to run off visible listed comparables. Those comparables moved: 14 of 20 covered names rose and the median move was +7.9%. FOR ADVISORS Lead with the Coverage and Evidence File The period's dominant theme was regulatory and reimbursement progress, not transactions. The evidence to lead with is concrete: an FDA advisory committee vote in favour for GRAIL, Inc. (GRAL), 510(k) clearance and new data licensing at Tempus AI, Inc.

7. 07
   SOURCES & METHODOLOGY

   Sources, Methodology and Important Notice

   This slide explains the sources and methodology behind every figure in this update, including the important notice.

   Every figure in this update links back to the specific filing, price record or article it was taken from, so each number here can be checked against its original source. We rely on a fixed source hierarchy — SEC filings, press releases and established outlets — and calibrated language throughout to keep driver reads separate from recorded fact. So what: this page is the reference for how the numbers and reads in this deck were built, not a claim beyond what the record supports.

   Everything on this page

   SOURCES & METHODOLOGY Sources, Methodology and Important Notice How this bi-weekly update is built and what each kind of statement rests on · September 14–28, 2026 · market data through 2026-09-28 Every figure in this update links to the record it was taken from; the publishers and filings drawn on for the period are listed above. Clinical Laboratory Services Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice 7 OBSERVED DATA Bi-Weekly stock moves are computed close-to-close over the stated window from the platform’s price series. Deal records, values and multiples come from the platform’s transaction record (SEC 8-K extractions) exactly as recorded; each figure links to its citation. Treasury rates come from the platform’s Treasury series and are shown only when the 10-year moved at least ten basis points over the window (it did not in this window, so no rate figures appear). UNIVERSE QUALITY The update universe is the platform’s approved company set for this sector, subject to a $100M market-cap floor so small, loosely related names cannot dominate the statistics. 2 names below the floor were excluded from movers and statistics for this window. EVENTS & NEWS Company events are in-window 8-K filings; news items are publisher-sourced headlines fetched for the window (and any externally supplied items, marked as such). Operational and strategic developments (deals, partnerships, launches, expansion, guidance, leadership, regulatory outcomes) are shown first; capital-return mechanics and conference appearances are limited to one each. Every event links to its source. The deck never asserts an event that has no linked record. SOURCE HIERARCHY News is admitted in a fixed order of reliability: SEC filings first, then company press releases and investor-relations communications, then transaction documents, then established outlets (Reuters, CNBC, The Wall Street Journal, Barron’s and peers). Video and social platforms — including YouTube — are never used as sources. DRIVER ATTRIBUTION A stock move is linked to an event only when the event falls inside the window, and only in calibrated language ("the move appears to reflect…", "shares moved following…"). Where no driver is recorded, the page says so and compares the move to the sector median instead. ANALYTICAL INTERPRETATION "Why it matters", "why the deal happened" and the what-it-means page are NeuraCap analytical views drawn from the recorded evidence, and are labeled as such. INHERITED CONTEXT The standing sector view (thesis, valuation lens, sector median and tiering) is inherited from the NeuraCap sector study run_20260929T164450Z_538_prod (market data as of 2026-09-28) — distilled, never re-derived. That report’s own sources page governs its content; this update reads the period against it. IMPORTANT NOTICE This report is informational only. It is not investment advice, not a recommendation to buy or sell any security, and not an offer of any kind. Readers should perform their own diligence before acting on anything described here. Linked sources this two-week period: prnewswire.com · businesswire.com · globenewswire.com

More coverage in Health Care

• Sector Report · Sep 28, 2026Clinical Laboratory Services Sector Outlook — September 2026
• Sector Report · Sep 28, 2026Neurology and CNS Therapeutics Sector Outlook — September 2026
• Bi-Weekly Update · Sep 28, 2026Oncology Therapeutics Bi-Weekly Industry Events & M&A Update — September 14–28, 2026
• Bi-Weekly Update · Sep 28, 2026Neurology and CNS Therapeutics Bi-Weekly Industry Events & M&A Update — September 14–28, 2026